



BY FAX / E-MAIL AND CONFIRMATORY COPY BY HAND DELIVERY

November 8, 2012

The Secretary
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai 400 023

Dear Sir,

Re: Update on SEZ Indore formulations manufacturing unit

Further to our letter dated 20th July, 2012 informing you that the US-FDA, following an inspection, has found acceptable our oral solid dosage formulations manufacturing facility situated at Pharmazone, SEZ Indore, Pithampur, Madhya Pradesh, we now wish to inform you that during the course of our internal quality assurance review, we have noticed a few non-conformances at the said manufacturing unit.

The Company has voluntarily referred these to the US-FDA and the same is under discussion with them for an appropriate resolution.

Till such time this issue is resolved to the satisfaction of the US-FDA, no dosage formulations manufactured at this manufacturing unit will be commercialized for the US market.

Thanking you

Yours faithfully
For Ipca Laboratories Limited

Harish P. Kamath
Company Secretary

Cc: The Secretary
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Flr, Plot # C/1
G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051.

Ipca Laboratories Ltd.

www.ipca.com

142-AB, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4747 F: +91 22 2868 6954
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613